Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Klinika Hamtologii Uniwersytetu Medycznego (medical University of Lodz)
Lodz, Poland
Tadeusz Robak, ProfessorNot, yet, recruiting
- Royal Marsden Hospital and Institute of Cancer Research
Surrey, United Kingdom
Claire Dearden, MDNot, yet, recruiting
- Stanford University School of Medicine
Stanford, California, United States
Steven E Coutre, MDNot, yet, recruiting - Cancer Center of Northwestern University
Chicago, Illinois, United States
Martin Tallman, MDNot, yet, recruiting - Warren Grant Megnuson Clinical Center - Nci Clinical Trials Referral Office
Bethesda, Maryland, United States
Robert J Kreitman, MDRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Apr 2007
- Primary completion
- —
- Completion
- —
- Last update posted
- 18 Apr 2007
- Registered enrollment
- 40
- Registry id
- NCT00462189
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.